About: Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.23 (-7.08%)
ERNA NASDAQ Eterna Therapeutics Inc
Eterna Therapeutics Inc share price
ERNA price activity
Last Price
$2.230
Change (24hr)
-0.17 USD (-7.08%)
Volume
30.37K
Volume (4w avg)
-
Open
$2.40
Day Range
$2.14 - $2.40
Previous Close
$2.40
Last Trade
12 Oct, 8:17 pm GMT+0
Delayed
12 Oct, 8:17 pm GMT+0
ERNA price performance
Delayed
12 Oct, 8:17 pm GMT+0
ERNA Market Signals